Trevi Therapeutics Q2 net loss $7.1M; cash $94.2M; three chronic cough trials on track for H2 2023

Trevi Therapeutics, Inc.

2023-Q2 EPS reported -$0.14

Net loss of $7.1M in Q2 2023 vs. $8.1M in Q2 2022; R&D expenses rose to $5.8M.
Cash, cash equivalents and marketable securities $94.2M at June 30, 2023.
Plans to initiate three chronic cough trials (Phase 2b IPF, Phase 1b IPF, Phase 2a RCC) in H2 2023 remain on track.
Human Abuse Potential study delayed due to IV butorphanol shortage from supplier tornado damage.
Phase 2 CANAL trial data published in NEJM Evidence; term loan of $6.5M repaid in May 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Trevi Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8..

Period: the quarter ended June 30, 2023
Net income: Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8.
Result: reported results

Exact text from the filing

On August 10, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the "Company") announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.